On Tuesday, October 9, 2018, U.K. Life Science Symposium in Nihonbashi: Aging, Gene Editing & AI was held in Large Conference Room 201, Nihonbashi Life Science Building. The event was sponsored by MedCity and Northern Health Science Alliance, co-sponsored by LINK-J.
Following last year's symposium, U.K. Life Science Symposium in Nihonbashi was hosted by MedCity and Northern Health Science Alliance. Researchers, universities, research institutions and others in the state-of-the-art healthcare field in the U.K. explained their findings in the life science, aging, gene editing and AI.
This symposium, co-hosted by LINK-J, was a co-event associated with the "1st Well Aging Society Summit Asia-Japan"*1 at Mitsui Hall on the same day, similar to "GLOBAL LIFE SCIENCE CLUSTER SESSION" (hosted by LINK-J). As it was held before BioJapan 2018 at Healthcare Innovation Weeks Asia - Japan 2018*2 sponsored by the Ministry of Economy, Trade and Industry, this symposium attracted many overseas visitors.
*1 1st Well Aging Society Summit Asia-Japan
The Ministry of Economy, Trade and Industry held the 1st Well Aging Society Summit Asia-Japan on October 9, 2018, as an international conference aiming at renewing investments in the healthcare businesses from domestic and overseas investors, corporations and others.
*2 Healthcare Innovation Weeks Asia - Japan 2018
For two weeks starting on October 9, many healthcare events were held in Japan. The Ministry of Economy, Trade and Industry created the unified brand Healthcare Innovation Weeks Asia-Japan 2018 to promote effective public relations activities in cooperation with these events. This was intended to effectively facilitate events with a large number of domestic and overseas visitors and promote investments in the healthcare businesses through a centralized dissemination of information. It also aimed to externally demonstrate Japan's presence in the healthcare field by sharing the superior services and research and development in the healthcare field in Japan.
In addition, to solve problems concerning healthcare, this event expected to foster international cooperative relationships leading to matches between overseas innovations and Japanese domestic needs, creating a unique and effective healthcare industry that leads to longer, healthy lives in Japan and overseas.
12:00-12:25 Welcome and Introductions
• Sarah Haywood- Chief Executive Officer, MedCity
Phil Jackson - Projects Director, MedCity
• Suzanne Ali-Hassan - Northern Health Science Alliance
• Aki Soyama - CEO, Link-J
• Yoshiaki Tsukamoto - Executive Director, Japan Bioindustries Association
12:25-13:15 Genotype to Phenotype: Interpretation, Translation and Innovation
• Dr. Rebecca Wilson, Head of Corporate Partnerships, Faculty of Natural Sciences, ImperialCollege London
"Imperial College London" Imperial College London was introduced as well as White City Campus, a new placed facility.
• Dr. Fiona Pereira PhD, Head of Business Development and Strategy, National Phenome Centre, Imperial College London
"Systems Biology for Maximising efficiency of translational medicine" （Research by Dr. Jia Li, Senior Lecturer, Faculty of Medicine, Department of Surgery & Cancer, Imperial College London, was shared. Although she was in Japan, she was absent due to a lecture at another institute.)
Summary of systems biology, followed by the relationship between obesity surgery and intestinal bacterial flora
• Professor Joanne Hackett, Chief Commercial Officer, Genomics England
"Genomics England: Leading the healthcare revolution using clinical and genomic data"
An introduction of Genomics England which British Department of Health and Human Services
established for 100,000 Genome Projects (2014-2018) , Genomics England Clinical Interpretation Partnership (GeCIP) as well. The next promotion is 5 million genome projects during the next five years.
13:15-13:20 Company infoshot
A scientific communication studio featuring manipulations that used medical animation and education, VR, interactions and visual sense was introduced.
13:30-14:00 Artificial Intelligence and Healthcare: What the future holds
• Dr. Namshik Han, Head of Computational Biology, Milner Therapeutics Institute, University of Cambridge
"Artificial Intelligence & Healthcare What the future holds"
AI as a method or tool, significance of data, causes of failures, reduction of research costs, systematization of research and more. LifeArc was introduced, a medical research and charity institution with 25 years of history of support for scientists and related institutes to reform research on therapy and diagnosis for patients.
14:05-14:10 Short Rest
14:10-14:45 Innovations in Neurological Medicine
• Prof Mimoun Azouz, Chair of Translational Neuroscience, University of Sheffield
"Research & Innovation in Neurodegeneration"
Sheffield Institute for Translational Neuroscience's research on neuropathy and neurodegenerative diseases was reported.
14:50-14:55 Company Infoshot
Invicro, LLC, a contract research organization (CRO) belonging to the Konica Minolta Group, contributes to realize innovative drug development through analysis of the digital image of molecules in collaboration with Ambry Genetics, another Konica Minolta Group company focused on genetic testing and analysis. Current stages of therapeutic drugs for neurodegenerative diseases and others were reported, and examples of digital image analysis were explained.
15:00-15:35 Dementia Research Institute and University College London
"UCL Populations & Lifelong Health and Neuroscience Research"
• Narges Amini, Senior Business & Innovation Manager, University College London
The history of UCL, its medical research and the results were explained.
• Lorna Ravenhill Ph.D, Senior Business & Innovation Manager, University College London
Efforts and strengths of UCL in the neuroscience field and cases in this field were explained.